March 22, 2021

PKI logo.png

Stock Wealth Safely selects PKI as a company with good prospects that is starting to show some price momentum

PKI (Perkinelmer) provides diagnostic products and services to the life sciences. It has a leading position in the newborn and maternal areas and is growing its presence in  other diagnostics and analytical areas. International growth holds great potential.

PKI has beaten expectations in the last 4 quarters by increasing amounts. Earnings estimates have climbed over the past 90 days.The 20 day moving average is 126.15, 50 day – 138.86, 100 day – 138.19,  and 200 day – 126.04. RSI is 52.82. ADX is 23. PAR turned to sell March 16 and the 4 day SMA crossed the 9 day. MACD turned up March 15. OBV is slightly up.


PKI closed at 128.13 on March 12, appears to be climbing, and remains well below the 161.64 consensus target.

TAP logo.jpg

Stock Wealth Safely selects TAP as an undervalued company with a good strategy for growth.

TAP (Molson Coors Beverage) is one of the largest brewing companies in the world. It has many established brands and is aggressively growing through acquisitions in markets such as craft beer and seltzers.

TAP beat expectations in 3 of the last 4 quarters and the miss last quarter caused a drop in the stock price which should be a buying opportunity.

The 20 day moving average is 46.85, 50 day – 48.35, 100 day – 46.14, and 200 day – 41.22. RSI is 63.35 and ADX is 17. PAR has been a buy since February 23 and MACD since March 5. OBV is strongly up.

TAP closed at 49.85 on March 22 and appears underpriced compared with its prospects. The price should increase toward the 52 weeks high of 56.11.

             March 1, 2021


Stock Wealth Safely selects AMGN (Amgen) as an undervalued company that should grow in value.

AMGN is a large biotechnical company with strong track record for successful product development. It has a number of new drugs that should offset competition from biosimilars for its older drugs. AMGN has good cash flow because of cost cutting and improved manufacturing and this should help its pricing for its own biosimilars. The dividend has recently been increased and is now a very attractive 3.1%.

AMGN has exceeded expected earnings in each of the last 4 quarters.

PSAR is sell, ADX 21, RSI 37.05 and OBV dropping. There should be resistance at 220.00. The 20 day moving average is 234.13, 50 day – 235.88, 100 day – 233.03 and 200 day – 237.23.

AMGN closed at 227.04 on March 1 and we anticipate the price is headed for the consensus target of 254.47.

CVS .png

Stock Wealth Safely selects CVS (CVS Health Corp) because of strong prospects and a reasonable price.

CVS is becoming the predominant integrated provider of health services combing the largest pharmacy benefit manager with the largest retail pharmacy chain. It is also involved in health insurance since the purchase of Aetna.  CVS is further expanding its services by including medical clinics in its stores with the aim of improving health as well as being synergistic with its other divisions. This unique structure should become increasingly profitable.

CVS has beaten estimates in the last 4 quarters.

The 20 day moving average is 71.61, 50 day – 71.76, 100 day – 68.24 and 200 day – 65.63. PSAR has been a sell since February 16 with ADX relatively weak at 23. RSI is 41.69 and OBV has been dropping. There may be a resistance around 68.00.

CVS closed at 69.28 on March 1 and should climb towards its consensus 85.72 target.​